Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220

Optimal management of superior sulcus tumors remains challenging.  This SWOG protocol was a feasibility study of the utility of consolidation therapy with docetaxel in addition to cisplatin-etoposide, 45Gy, and possible resection.   Of 46 registered pts, 86% completed induction therapy, 66% underwent resection, and 45% completed consolidation therapy.  The R0 resection rate in surgical pts was 97%, and the complete or near-complete pathologic response rate in resected patients was 72%.  Overall 3-year survival was 61%.